Edgemoor Investment Advisors, Inc. Bristol Myers Squibb CO Transaction History

Edgemoor Investment Advisors, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$61.48 - $73.72 $13,833 - $16,587	225 Added 1.08%	21,145 $1.54 Million
Q4 2021 Feb 09, 2022	BUY	$53.63 - $62.52 $42,904 - $50,016	800 Added 3.98%	20,920 $1.3 Million
Q3 2021 Nov 02, 2021	SELL	$59.17 - $69.31 $9.64 Million - $11.3 Million	-162,872 Reduced 89.0%	20,120 $1.19 Million
Q2 2021 Aug 11, 2021	SELL	$61.91 - $67.42 $464,944 - $506,324	-7,510 Reduced 3.94%	182,992 $12.2 Million
Q1 2021 May 12, 2021	BUY	$59.34 - $66.74 $71,208 - $80,088	1,200 Added 0.63%	190,502 $12 Million
Q4 2020 Feb 11, 2021	BUY	$57.74 - $65.43 $210,577 - $238,623	3,647 Added 1.96%	189,302 $11.7 Million
Q3 2020 Nov 10, 2020	BUY	$57.43 - $63.64 $39,626 - $43,911	690 Added 0.37%	185,655 $11.2 Million
Q2 2020 Aug 05, 2020	BUY	$54.82 - $64.09 $781,459 - $913,602	14,255 Added 8.35%	184,965 $10.9 Million
Q1 2020 May 06, 2020	SELL	$46.4 - $67.43 $59,763 - $86,849	-1,288 Reduced 0.75%	170,710 $9.52 Million
Q4 2019 Feb 04, 2020	BUY	$49.21 - $64.19 $122,680 - $160,025	2,493 Added 1.47%	171,998 $11 Million
Q3 2019 Nov 06, 2019	BUY	$42.77 - $50.71 $15,354 - $18,204	359 Added 0.21%	169,505 $8.6 Million
Q2 2019 Aug 09, 2019	BUY	$44.62 - $49.34 $1.41 Million - $1.56 Million	31,518 Added 22.9%	169,146 $7.67 Million
Q1 2019 May 08, 2019	BUY	$45.12 - $53.8 $6.21 Million - $7.4 Million	137,628 New	137,628 $6.57 Million
Q4 2018 Jan 31, 2019	SELL	$48.76 - $63.23 $180,460 - $234,014	-3,701 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$55.23 - $63.74 $204,406 - $235,901	3,701	3,701 $236,000

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $126B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Edgemoor Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Edgemoor Investment Advisors, Inc. with notifications on news.